Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2006-05-02
2006-05-02
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000, C424S497000, C424S464000, C424S465000, C424S469000, C424S470000
Reexamination Certificate
active
07037529
ABSTRACT:
The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 μm, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layer(s).The invention also provides a method for preparing said composition.
REFERENCES:
patent: 2953497 (1960-09-01), Press
patent: 4412986 (1983-11-01), Kawata et al.
patent: 4524060 (1985-06-01), Mughal et al.
patent: 4629624 (1986-12-01), Grouiller et al.
patent: 4684516 (1987-08-01), Bhutani
patent: 4721709 (1988-01-01), Seth et al.
patent: 4800079 (1989-01-01), Boyer
patent: 4895726 (1990-01-01), Curtet et al.
patent: 4992277 (1991-02-01), Sangekar et al.
patent: 5073379 (1991-12-01), Klimesch et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5545628 (1996-08-01), Deboeck et al.
patent: 5633015 (1997-05-01), Gilis et al.
patent: 5776495 (1998-07-01), Duclos et al.
patent: 6027747 (2000-02-01), Terracol et al.
patent: 6042847 (2000-03-01), Kerc et al.
patent: 2002/0009496 (2002-01-01), Stamm et al.
patent: 2002/0114839 (2002-08-01), Stamm et al.
patent: 2002/0168413 (2002-11-01), Stamm et al.
patent: 2003/0104051 (2003-06-01), Stamm et al.
patent: 2003/0104060 (2003-06-01), Stamm et al.
patent: 2004/0057997 (2004-03-01), Stamm et al.
patent: 2004/0057998 (2004-03-01), Stamm et al.
patent: 2004/0057999 (2004-03-01), Stamm et al.
patent: 2004/0058004 (2004-03-01), Stamm et al.
patent: 2004/0058005 (2004-03-01), Stamm et al.
patent: 2004/0092597 (2004-05-01), Stamm et al.
patent: 960670 (1975-01-01), None
patent: 2142848 (1994-03-01), None
patent: 2219475 (2002-07-01), None
patent: 2372576 (2004-02-01), None
patent: 0 330 532 (1989-08-01), None
patent: 0 519 144 (1992-12-01), None
patent: 0 761 208 (1997-03-01), None
patent: 0 793 958 (1997-09-01), None
patent: 0 256 933 (1998-02-01), None
patent: 0 952 829 (2003-03-01), None
patent: WO 82/01649 (1982-05-01), None
patent: WO 97/12581 (1997-04-01), None
patent: WO 98/31360 (1998-07-01), None
patent: WO 98/31361 (1998-07-01), None
Temeljotov et al, Acta Pharm., 46:131-136 (1996).
Opposition to EP 0 952 829 (Dec. 11, 2003) (English language translation).
Opposition to EP 0 952 829 (Dec. 11, 2003) (original French language document).
Laboratoires Fournier Lab Notebook No. 1 (Feb. 18, 1997 to May 15, 1997).
Laboratoires Fournier Lab Notebook No. 2 (May 16, 1997 to Jul. 30, 1997).
Complaint, US District Court for the District of Delaware, Civil Action No. 04-350,Reliant Pharmaceuticals v. Abbott Laboratories et al(Jun. 1, 2004).
Handbook of Pharmaceutical Excipients, Second Edition, pp. 392-399 (1994).
Laboratoires Fournier S.A. document entitled “Fenofibrate Tablets 54-60 mg Dissolution Test Conditions Development Studies, Dissolution Test Specification Recommendations” Dec. 1997.
“Second Amended Answer, Affirmative Defenses, and Counterclaims” filed by Teva on Jul. 29, 2005, in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., DE, CA No. 02-1512.
“First Amended Counterclaims” filed by Impax on Sep. 23, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Amended Complaint” filed by CVS Pharmacy et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Amended Complaint” filed by Walgreen Co. et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Complaint”0 filed by Painters' to District Council No. 30 et al on Sep. 23, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“First Amended Complaint” filed by Louisiana Wholesale Drug Co. et al, on Oct. 3, 2005 in In Re TriCor Direct Purchaser Antitrust Litigation, Delaware, CA No. 05-340.
“Defendants Responses to Plaintiffs Interrogatories” filed by Impax on Aug. 6, 2003 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Amended Answer” filed by Impax on Jan. 1, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Reply Memorandum” filed by Impax on Feb. 25, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Memorandum Opinion” by District Judge Jordan dated May 6, 2005 in Abbott Laboratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.
“Opening Brief in Support of Motion for Summary Judgment” by Teva filed on Dec. 23, 2004 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512.
“Opening Brief in Support of Motion for Summary Judgment” by Teva filed on Dec. 10, 2004 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512.
“Memorandum Opinion” by District Judge Jordan dated May 6, 2005 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512.
Opposition to European Patent No. 1 273 293 filed on Sep. 2, 2005 by Ethypharm (French Language Document).
Opposition to Israel Patent No. 130790 dated May 4, 2005 by Teva; and Remarks in Response to Opposition filed on Sep. 23, 2005. (English Language Translations).
Munoz et al, Atherosclerosis, 110(Suppl.):S45-S48 (1994).
Pharmaceutical Pelletization Technology, Marcel Dekker, Inc., vol. 37, pp. 1-13; 160-161; and 234-235 (1989).
Modern Pharmaceutics, Third Edition, Marcel Dekker, Inc., pp. 131-133 and 335-336 (1996).
Pharmaceutical Dosage Forms, Tablets, Second Edition, Marcel Dekker, Inc., pp. 5-28; 88-107; 133; 142; 160-165; and 260-267 (1989).
Shepherd, Atherosclerosis, 110(Suppl.):S55-S63 (1994).
Adkins et al, Drugs, 54(4):615-633 (Oct. 1997).
Letter from Teva/Novopharm to Fournier Pharma Inc. regarding Invalidity and Ambiguity of Canadian Patent Nos. 2,219,475 and 2,372,576 (pp. 1-15) (Sep. 19, 2005).
Seth Pawan
Stamm Andre
Laboratoires Fournier
Page Thurman K.
Sheikh Humera N.
Venable LLP
LandOfFree
Fenofibrate pharmaceutical composition having high... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fenofibrate pharmaceutical composition having high..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fenofibrate pharmaceutical composition having high... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529616